MichaelRBishopMDFACP, FASCO

PubMed

• 33 citations
  Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an ...
  Bijal D Shah, Armin Ghobadi, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel
  Journal of Hematology & Oncology. 2022-12-10
• 327 citations
  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
  Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C Logan, Nicolas Boissel
  Lancet. 2021-08-07
• 156 citations
  Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
  Michael Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu
  Journal for Immunotherapy of Cancer. 2018-12-04

Journal Articles

• High-Dose Sirolimus And Immune Selective Pentostatin Plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-Versus-Tumor Responses  
  Fowler DH, Mossoba ME, Halverson DC, Kurlander R, Blacklock Schuver B, Carpenter AE, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche JC, Sportes C, ..., Clin Cancer Res, 1/12/2015
• Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients  
  Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y, Bone Marrow Transplant, 1/8/2015
• Symptom distress predicts long-term health and well- being in allogeneic stem cell transplantation survivors  
  Bevans MF, Mitchell SA, Barrett JA, Bishop MR, Childs R, Fowler D, Krumlauf M, Prince P, Shelburne N, Wehrlen L, Yang L, Biol Blood Marrow Transplant, 1/1/2014
• Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation  
  Fisher V, Khuu H, David-Ocampo V, Byrne K, Pavletic S, Bishop M, Fowler DH, Barrett AJ, Stroncek DF, Transfusion, 1/1/2014
• Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Trans...  
  de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kroger N, Wayne AS, Schmid C, Biol Blood Marrow Transplant, 1/1/2013
• Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Trans...  
  Avigan D, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kroger N, Wayne AS, Hsu KC, Biol Blood Marrow Transplant, 1/1/2013
• Donor Lymphocyte Infusion: Beauty Is in the Eye of the Beholder  
  Bishop MR, Biol Blood Marrow Transplant, 1/1/2013
• Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Trans...  
  Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kroger N, Wayne AS, Landau DA, Wu CJ, Biol Blood Marrow Transplant, 1/1/2013
• Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation  
  Salit RB, Fowler DH, Dean RM, Pavletic SZ, Hakim FT, Steinberg SM, Hardy NT, Sportes C, Gress RE, Bishop MR, Biol Blood Marrow Transplant, 1/1/2013
• Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Trans...  
  Wayne AS, Giralt S, Kroger N, Bishop MR, Biol Blood Marrow Transplant, 1/1/2013
• Phase II clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation  
  Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy ..., Blood, 1/1/2013
• Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience  
  Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Huss..., Bone Marrow Transplant, 1/1/2013
• Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion  
  Liu HT, Liu DH, Huang XJ, Artz A, Bishop MR, Chin Med J (Engl), 1/1/2013
• Effects of Rapid Donor T-lymphocyte Engraftment on Disease Control and Graft versus Host Disease in Persons Undergoing Reduced-Intensity Conditioning Allotransplantati...  
  Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ, Exp Hematol, 1/1/2013
• Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Challenges  
  Shah NN, Bacher U, Fry T, Calvo K, Stetler-Stevenson M, Arthur DC, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy NM, Wayne AS, Am J Hematol, 1/12/2012
• Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients  
  Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash, H, Bryant K, Bi..., Bone Marrow Transplant, 1/9/2012
• Monitoring and preventing relapse after allogeneic hematopoietic stem cell transplantation for myeloid malignancies  
  Bacher U, Talano JA, Bishop MR, Biol Blood Marrow Transplant, 1/1/2012
• Reduced Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultra-High Risk Pediatric Sarcomas  
  Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, Humphrey JL, Rager A, Richards K, Wayne AS, Mackall CL, Biol Blood Marrow Transplant, 1/1/2012
• Conditioning regimens for allotransplants for diffuse large B-cell lymphoma - myeloablative or reduced intensity?  
  Bacher U, Klyuchnikov ES, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson JN, Isola LM, Inwards DJ, Lap..., Blood, 1/1/2012
• Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Therapy for Relapse After Allogeneic Hematopoietic Stem Cell Transplantation  
  Hardy NM, Fellowes V, Rose J, Pittaluga S, Stetler-Stevenson M, Hakim FT, Steinberg SM, Odom J, Blacklock B, Layton P, Avila D, Taylor T, Fowler DH, Khuu H, Levine BL,..., Blood, 1/1/2012
• Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis  
  Cook RJ, Wang Z, Arora M, Lazarus HM, Kasow KA, Champagne MA, Saber W, van Besien KM, Hale GA, Copelan EA, Elmongy M, Ueno NT, Horn BN, Slavin S, Bishop MR, Stadtmauer EA, Bone Marrow Transplant, 1/1/2012
• Tailored lymphodepletion and tumor reduction with EPOCH-F(R) induction followed by reduced intensity allogeneic stem cell transplantation in patients with malignant ly...  
  Floisand Y, Brinch L, Gedde-Dahl T, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen G, Fossa A, Lehne G, Baggerod E, Kvalheim G, Bishop MR, Fowler DH, Kolstad A, Bone Marrow Transplant, 1/1/2012
• Similar Outcomes Using Myeloablative Versus Reduced Intensity Allogeneic Transplant Preparative Regimens For AML Or MDS  
  Luger SM, Ringden O, Zhang MJ, Perez WS, Bishop MR, Bornhauser M, Bredeson CN, Cairo MS, Copelan EA, Gale RP, Giralt SA, Gulbas Z, Gupta V, Hale GA, Lazarus HM, Lewis ..., Bone Marrow Transplant, 1/1/2012
• Overview of Non-Hodgkin's Lymphoma  
  Guerard E, Bishop MR, Dis Mon, 1/1/2012
• Dose adjusted EPOCH-fludarabine with and without rituximab for lymphoid malignancies prior to reduced-intensity allogeneic hematopoietic stem cell transplantation  
  Salit RB, Fowler DH, Wilson WH, Pavletic SZ, Dunleavy K, Hakim F, Dean RM, Steinberg SM, Hughes T, Odom J, Kelly Bryant K, Bishop MR, J Clin Oncol, 1/1/2012
• Join now to see all

Books/Book Chapters

• Goldman-Cecil Medicine 
  Chapter: Hematopoietic Stem Cell Transplantation 
  Page 1198 - 1205Keating A and Bishop MREditors: Goldman L, Schafer A.Elsevier Saunders, Philadelphia, PAEdition 25th,2016
• Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians 
  Chapter: Relapse After hematopoietic Stem Cell Transplantation 
  Page 719 - 732Bishop MREditors: Wingard JR, Gastineau DA, Leather HL, Snyder EL, Szczepiorkowski ZM.AABB, Bethesda, MDEdition 2nd,2015
• Hematopoietic Stem Cell Transplantation. Series: Cancer Treatment and Research 
  Editors: Bishop MR.Springer, New York, NY2009
• Hematopoietic Stem Cell Transplantation 
  Chapter: Principles and Overview of Allogeneic Hematopoietic Stem Cell Transplantation 
  Page 1 - 22Giralt S and Bishop MREditors: Bishop MR.Springer, New York, NY2009
• The Clinical Practice of Stem Cell Transplantation 
  Chapter: The Place of Stem Cell Transplantation in the Treatment of Breast Cancer 
  Page 123 - 136Hardy NM and Bishop MREditors: Treleaven J, Barrett AJ.ElsevierEdition 2nd,2009
• Clinical Oncology 
  Chapter: Hematopoietic Stem Cell Transplantation 
  Page 501 - 512Pavletic SZ and Bishop MREditors: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE.Churchill Livingston, Philadelphia, PAEdition 4th,2008
• Clinical Neoplastic Hematology 
  Chapter: Principles of Hematopoietic Stem Cell Transplantation to Treat Hematologic Malignancies 
  Page 975 - 984Bishop MREditors: Bolwell B, Kalaycio M, Sekeres M.McGraw-Hill Professional2007
• Hematology-Oncology Therapy 
  Chapter: Complications and Follow-up after Hematopoietic Stem Cell Transplantation 
  Page 674 - 693Boyiadzis MM and Bishop MREditors: Boyiadzis MM, Lebowitz PF, Frame JN, Fojo T.McGraw-Hill Professional2007
• Immunotherapy of Cancer 
  Chapter: Harnessing the Potential of Graft-versus-Tumor 
  Page 235 - 261Hardy NM and Bishop MREditors: Disis ML.Humana Press, Totowa, NJ2006
• American Society of Clinical Oncology Education Book 
  Chapter: Allogeneic Stem Cell Transplantation: Are We Curing More Patients? 
  Page 387 - 396Barrett AJ, Chao NJ, and Bishop MREditors: Perry M.American Society of Clinical Oncology, Alexandria, VA2006
• Living with Lymphoma 
  Adler EMEditors: Bishop MR (Introduction and scientific editor).John Hopkins University Press, Baltimore, MD2005
• Clinical Oncology 
  Chapter: Tumor Lysis Syndrome 
  Page 987 - 992Bishop MR, Cairo M and Coccia PFEditors: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE.Churchill LivingstonEdition 3rd,2004
• Clinical Bone Marrow Transplant: A Textbook 
  Chapter: Secondary Solid Tumors following Hematopoietic Stem Cell Transplantation 
  Bishop MR and Henslee-Downey PJEditors: Atkinson, K.Cambridge University PressEdition 3rd,2003
• American Society of Clinical Oncology Education Book 
  Chapter: Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Solid Tumors 
  Page 256 - 265Bishop MREditors: Perry M.American Society of Clinical Oncology, Alexandria, VA2003
• American Society of Clinical Oncology Education Book 
  Chapter: Adoptive Immunotherapy for Malignant Disease 
  Page 22 - 28Bishop MR and Fowler DHEditors: Perry M.American Society of Clinical Oncology, Alexandria, VA2003
• Updates: Principles and Practice of Biologic Therapy of Cancer 
  Chapter: Non-Myeloablative Allogeneic hematopoietic Stem Cell Transplantation as Adoptive Cellular Therapy 
  Bishop MREditors: Rosenberg SA.Lippincollt, Williams, & WilkinsEdition 3rd,2001
• Malignant Lymphoma 
  Chapter: Cytogenetics 
  Sanger WG and Bishop MREditors: Hancock, Selby, MacLennan and Armitage.Chapman & Hall Ltd2000
• Current Controversies in Bone Marrow Transplantation. 
  Chapter: Stem Cell Transplantation for Chronic Myelogenous Leukemia: Indications and Timing 
  Page 83 - 94Bishop MREditors: Bolwell BJ.Humana Press1999
• American Society of Clinical Oncology Education Book 
  Chapter: Bone Marrow Transplantation from Unrelated Donors 
  Bishop, MREditors: Perry M.American Society of Clinical Oncology, Alexandria, VA1998
• Yearbook of Cell and Tissue Transplantation 
  Chapter: Bone Marrow Transplantation 
  Page 3 - 12Armitage JO and Bishop MREditors: Lanza RP, Chick WL.Kluwer Academic Publishers, Netherlands1997
• Methods in Molecular Medicine: Antisense Therapeutics 
  Chapter: Continuous Infusion of Antisense Phosphorothioate Therapeutics 
  Page 201 - 212Iversen PL, Copple BL, Tewary HK, Bayever E, and Bishop MREditors: Agrawal S.Humana Press Inc.1996
• Clinical Oncology 
  Chapter: Tumor Lysis Syndrome. 
  Page 557 - 561Bishop MR and Coccia PFEditors: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE.Churchill Livingston1995
• Cell Therapy 
  Chapter: High-dose Chemotherapy with Cellular Support for Hematological Malignancies 
  Page 337 - 351Bierman PJ, Bishop MR, and Armitage JOEditors: Morstyn G, Sheridan W.Cambridge University Press1995
• Clinical Oncology 
  Chapter: Bone Marrow Transplantation. 
  Page 295 - 305Armitage JO, Bishop MREditors: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE.Churchill Livingston1995
• Bone Marrow Transplantation: Foundations for the 21st Century 
  Chapter: Detection of Minimal Residual Disease in Hematopoietic Tissues 
  Page 242 - 261Sharp JG, Bishop M, Chan WC, Greiner T, Joshi SS, Kessinger A, Reed E, Sanger W, Tarantolo S, Traystman M, and Vose JEditors: Sackstein R, Janssen WE, Elfenbein GJ.New York Academy of Science, New York, NY1995
• Join now to see all

Abstracts/Posters

• Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
  Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
  Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
  Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
  Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
  Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Cellular Immunotherapy Including Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-cells for Hematologic Malignancies 
  Chicago, IL - 1/30/2015
• Immunotherapy: Revolutionizing the Way We Treat Hematologic Malignancies 
  Champaign, IL - 1/27/2015
• Antibody-Based Strategies for st revention of Relapse after Allogeneic Hematopoietic Stem P Cell Transplantation 
  Istanbul, Turkey - 1/22/2015
• Hematopoietic Stem Cell Transplantation for Lymphoma 
  University of Chicago - 1/1/2015
• Con: Patients With Transformed DLBCL Should Receive An Autologous, Not An Allogeneic, Stem Cell Transplant In The Modern Era 
  Chicago, IL - 1/25/2014
• Transplant Options in Lymphoma 
  Chicago, IL - 1/17/2014
• Transplantation Update for Myeloma and Leukemia 
  Decatur, IL - 1/8/2014
• Cancer Immunotherapy Comes of Age: A Focus on Cellular Therapy for B-cell Malignancies 
  Toronto, Canada - 1/5/2014
• Monoclonal Antibody Therapy to Prevent Relapse after Hematopoietic Stem Cell Transplantation 
  Grapevine, TX - 1/2/2014
• The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation 
  San Diego, CA - 1/1/2014
• Adoptive Immunotherapy for Hematologic Malignancies: Dawn of a New Era 
  Evanston, IL - 1/23/2013
• Patients with Relapsed Follicular Lymphoma Should Receive Autologous Hematopoietic Stem Cell Transplantation 
  Berlin, Germany - 1/13/2013
• Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia 
  Methodist Hospital, Merrillville, IN - 1/7/2013
• New Developments in the Management of Hematological Malignancies and Transplant 
  McDonalds Campus, Oak Brook, IL - 1/2/2013
• 2012 AACR/ASCO Workshop: Methods in Clinical Cancer Research 
  American Association for Cancer Research, Vail, Colorado - 7/28/2012
• The Immune System as It Relates to Hematopoietic Stem Cell Transplantation 
  Medical College of Wisconsin - 1/20/2012
• New Developments in Bone Marrow Transplant: Progress in Biology and Therapy 
  New Orleans, LA - 1/17/2012
• Recent Advances in the Treatment of Non-Hodgkin's Lymphoma 
  Green Bay, WI - 1/17/2012
• Prevention Of Relapse Following Allogeneic HCT In Adult Patients With Myeloid Malignancies 
  San Diego, CA - 1/1/2012
• Clinical Trials 
  Suburban Hospital, Bethesda, MD - 1/24/2011
• Post HCT Relapse Treatment Strategies 
  Honolulu, HI - 1/19/2011
• Summary of the NCI 1st International Workshop on the Biology, Prevention and Treatment of Relapse after HCT 
  Honolulu, HI - 1/17/2011
• Anything New in the Prevention or Treatment of Relapse after Allogeneic HCT? 
  Dubrovnik, Croatia - 1/16/2011
• Acute Myelogenous Leukemia 
  1/1/2011
• Join now to see all

Other

• Alternative Donor Sources in Allogeneic Stem Cell Transplantation. 
  Bishop MR, Medscape Oncology
  1/1/1998
• Non-Hodgkin's Lymphoma and Autologous Stem Cell Transplantation: A Critical Review. 
  Bishop MR, Bierman PJ, Vose JM, Armitage JO, Revisions en Cancer
  1/1/1994
• Discovery--And Implications--Of a Single Human Bone Marrow Stem Cell. 
  Bishop MR, Oncology Bulletin
  1/1/1993
• Acute venous thrombosis: Therapeutic choices for superficial and deep veins. 
  Messmore HL, Bishop MR, Wehrmacher WH, Postgraduate Medicine
  1/1/1991
• Join now to see all